Faculty Directory

Home > Academics > Faculty Directory

Anders Lindroth

Suh, Yang Gun, M.D., Ph.D.(full-time professor)
Faculty Appointment
(title, department)

Assistant professor,
Department of Cancer Control and Population Health, NCC-GCSP, NCC
Area of Expertise
Radiation oncology & Immuno-oncology
Contact no
Previous Appointment(s) Held
Clinical assistant professor, Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Clinical fellow, Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Educational Background
2013 Ph.D., Medical Science & Engineering, KAIST, Daejeon, Republic of Korea
2008 M.S., Medicine, Yonsei University, Seoul, Republic of Korea
2004 B.S., Medicine, Yonsei University, Seoul, Republic of Korea
Research Interests (Please place in paragraph form)
Dr. Suh is a radiation oncologist who specialized in the treatment of lung cancer, sarcoma and hematologic malignancies. His research focuses on immunity against tumors. The ultimate goal of his research is to enhance the effect of anticancer therapies including radiotherapy and chemotherapy by modulating the host immunity and tumor microenvironment.
International Collaboration
2019 기타 Local ablative radiotherapy for oligometastatic non-small cell lung cancer: RADIATION ONCOLOGY JOURNAL. 37(3):149~155 (0)

2019 SCI-E Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study: CANCER RESEARCH AND TREATMENT. 51(3):1001~1010 (3.363)

2019 기타 Radiaion-induced sarcoma after breast cancer treatment: Two cases with different prognosis: 대한유방검진학회지. 16:25~31 (0)

2019 SCI Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo: BIOMATERIALS. 197:12~19 (10.273)

2019 SCI-E Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)

2019 SCI-E Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation: RADIATION ONCOLOGY. 14(1):4~4 (2.895)

2018 SCI-E Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer: Technology in cancer research & treatment. 17:1~9 (1.646)

2017 SCI-E Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea.: Cancer Research and Treatment. 50(2):335~344 (3.772)

2017 기타 Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer.: Radiation Oncology Journal. 35:241~248 ()

2016 SCI-E Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.: Cancer Research and Treatment. 49:669~667 (4.245)

2016 SCI Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas: Strahlenther Onkol. 192(9):649~657 (2.898)

2016 SCI Treatment outcomes of intensity-modulated radiotherapy versus 3D conformal radiotherapy for patients with maxillary sinus cancer in the postoperative setting.: Head & Neck. 38:E207~E213 (2.641)

2016 SCI-E Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation.: Technology in Cancer Research & Treatment. 15:122~129 (1.73)

2015 SCI Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma.: American Journal of Ophthalmology. 160:1111~1115 (3.871)

2015 SCI-E Blockade of Retinol Metabolism Protects T Cell-Induced Hepatitis by Increasing Migration of Regulatory T Cells.: Molecules and Cells. 38:998~1006 (2.09)

2014 SCI-E The role of radiotherapy in the management of POEMS syndrome.: Radiation Oncology. 9:265~273 (2.36)

2014 SCI-E Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy.: Digestive Diseases. 32:725~732 (1.832)

2014 SCI-E Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice.: Gut Liver. 8:526~535 (1.494)

2014 SCI-E Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds.: Plos One. Online:Published (3.534)

2014 SCI-E High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.: Japanese Journal of Clinical Oncology. 44:534~540 (1.747)

2014 SCI Feasibility and outcomes of hypofractionated simultaneous integrated boost-intensity modulated radiotherapy for malignant gliomas: a preliminary report.: Yonsei Medical Journal. 55:70~77 (1.263)

2013 SCI Activation of toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin-10 in mice.: Journal of Hepatology. 58:342~349 (9.858)

2012 SCI CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice.: Hepatology. 2012:1902~1912 (11.665)

2012 SCI Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors.: Annals of Hematology. 91:1785~1793 (2.615)

2011 SCI Hepatic stellate cells and innate immunity in alcoholic liver disease.: World Journal of Gastroenterology. 17:2543~2551 (2.24)

2011 SCI Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice: Hepatology. 53:1373~1382 (10.885)